Press Releases

Press Releases

Tampa-based firm's proven cardiac technology paired with one-of a-kind cutting edge technology to deliver improved care. 

Burns brings nearly two decades of experience in cardiovascular imaging, echocardiography education and clinical program leadership.

The newly cleared platform provides cardiac care teams with a continuous, consolidated view of hemodynamic and organ function status.

European Heart Journal publication of PIONEER IV data confirms QFR-guided PCI matches conventional strategies while reducing procedural complexity.

The acquisition deepens Integration Health's perfusion staffing capabilities through Perfusion Life's nationwide network.

Register today for the premier collaboration of interventional cardiovascular care providers in the Southwest United States.

Significant improvements in heart wall thickness, heart function and quality of life, as well as an excellent safety profile, were reported in an interim analysis of the BioVAT-HF clinical trial.

Exstent has appointed Matt Thompson its chief executive officer to lead the company’s next stage of global growth and expand access to its personalized external aortic support technology.

Tolpegin brings more than two decades of leadership experience with nonprofit medical organizations, including her role as the CEO of the Society of Cardiovascular Computed Tomography.

Data strongly support the technology for effective, efficient and safe probe placement versus blind intubation in TEE procedures.

Naples Comprehensive Health (NCH) announced that Joseph Lamelas, MD, an internationally renowned cardiothoracic surgeon and pioneer in minimally invasive cardiac surgery, will join the NCH Rooney Heart Institute in Naples on Oct. 15.

Integration Health announces the acquisition of ECMO Advantage, combining the industry's two leading ECMO service providers to create the definitive national platform for ECMO program development, specialized staffing, transport and education services.

Biome Analytics is set to launch the Biome Virtual Analyst — a groundbreaking AI-powered tool that gives hospitals immediate answers to complex performance, clinical, and financial questions without sifting through dashboards or reports.

New company structure enhances service delivery while preserving Innovative ECMO Concepts’ brand recognition.

The decision follows a request for reexamination by Egg Medical, which argued the patent covered technology that had already been invented.

Biome Analytics has launched Biome IMPACT, a new AI-enabled methodology to support cardiovascular performance improvement. The framework helps health systems identify opportunities, align stakeholders and track measurable results—without adding to the team’s workload.

Breakthrough autologous solution aims to provide lifelong durability for young heart patients.

Biome Analytics is proud to welcome Javier Valle, MD—renowned interventional cardiologist and national quality leader—as our new chief medical officer. His deep clinical expertise and commitment to high-value care will help shape the future of cardiovascular performance improvement.

Hospitals can now measure and improve outcomes through the lens of social and economic disparities by integrating social determinants of health (SDOH) directly into their performance analytics.

Special T MRI, an independent, state-of-the-art imaging center located in Fenton, Missouri, is proud to announce the launch of its advanced cardiac MRI imaging program aimed at enhancing early detection and management of heart disease through non-invasive cardiac MRI technology.

 

 

NASA is constantly working toward enhancing astronaut safety through the development of next-generation spacesuits. In collaboration with the German medical technology developer Corscience, a crucial milestone has been achieved in advancing the design and functionality of spacesuits for the upcoming Artemis lunar missions.

This achievement highlights Positron's commitment to providing innovative imaging solutions that enable healthcare providers to elevate patient care and achieve superior clinical outcomes.

This partnership underscores Peak Heart & Vascular’s dedication to improving patient outcomes through research, education and the latest medical technologies, ensuring they remain at the forefront of cardiovascular care in Arizona.

Following its recent $43 million Series B funding, the company is expanding its data integration capabilities to include a broader range of devices, including wearables, heart failure monitoring, and remote patient monitoring.

Congratulations to Stanford Medicine on winning the 2023 Hearst Health Prize for its artificial intelligence solution that helps identify patients at risk for heart attack by scoring incidental coronary artery calcium (CAC) on non-gated chest CTs.

Predictive model generation for pre-planning a cardiac procedure now reimbursable by Medicare at approximately $1,000 per model

 

Late-Breaking Science sessions reveal revolutionary findings on severe aortic stenosis and mild-to-severe mitral regurgitation identification through innovative AI technology.

 

| Submitted by: Keystone Perfusion Services, PC

The company's multifaceted healthcare staffing solutions play a pivotal role in transforming patient care and elevating industry standards.

 

The agreement formally endorses Corazon’s cardiovascular accreditation.

Arineta Cardio Imaging is excited to announce the FDA 510(k) clearance of the SpotLight and SpotLight Duo family of cardiovascular CT scanners.

 

Researchers and engineers at Mayo Clinic and Ultromics developed technology that can detect HFpEF using a single A4C echocardiogram clip, to help clinicians detect a complex form of heart failure easily and accurately. 

 

The Midwest company will begin offering EchoSolv, an artificial intelligence clinical decision support platform designed to help detect severe aortic stenosis, to providers throughout the country.

 

| Submitted by: DASI Simulations

Precision TAVI is the first FDA-approved predictive modeling tool for medical teams planning TAVR procedures.

 

 

RecoverRite’s Online Heart Learning Center to feature ACC’s CardioSmart patient tools and resources.

PulseAI, a leader in the development of cutting-edge AI-powered ECG software, has released the results of a clinical study that has shown the superiority of its deep learning AI over the Apple Watch ECG algorithm in the detection of atrial fibrillation.

 

NAPLES, Fla. – February 20, 2023   The NCH Healthcare System is proud to announce a $20 million naming gift from the Rooney Foundation, which is the philanthropic arm of the former U.S. Representative for Florida's 19th congressional district and his wife, Francis and Kathleen Rooney.  In recognition of increasing their $8 million pledge announced last July, the entire cardiac program across NCH Healthcare System will be renamed “The Rooney Heart Institute.”

NAPLES, Fla. – February 21, 2023   On the heels of our historic $20 Million gift announcement made last week, NCH is proud to announce yet a second $20 million naming gift in as many weeks from Diana and Don Wingard.  This generous gift will provide the necessary funds to ensure that the NCH Stroke program continues to provide the highest level of care and treatment to patients in Southwest Florida.  Additionally, in recognition of the extraordinary pledge, the entire stroke program across NCH will be renamed the “Wingard Stroke Institute.”

When using this service, patients have the ability to upload and share data without limitations. From radiology CDs to PDFs or JPG files, patients can use their smartphone connected to the Patient Image Exchange app and upload images, share lab results, immunizations records, nurses’ notes, dental images and much more.

 

Ancora Heart has hired senior financial leader David J. Tucker as its chief financial officer. This is the company's second C-suite hire in 2022, following the addition of Mark Miles as chief commercial officer in June.

Geneticure, a global leader in the genetic variability of response to hypertension treatments, presented data at the 2022 American Heart Association Scientific Sessions meeting from a recent clinical study in which they were able to successfully predict patients who will respond to renal denervation (RDN). In addition, the Geneticure test for renal denervation also identified patients with an increase in blood pressure, following the procedure.

Long-awaited milestone gives physicians and their patients greater access to prescription cardiac arrhythmia detection solutions, including the company’s Cardea SOLO™ ECG System

DUBLIN and ROME - Aug. 29, 2016 - Medtronic plc (NYSE:MDT) today announced results from the Cardiac Resynchronization Therapy Efficacy Enhancement (CRTee) study. The study showed that the Medtronic-exclusive device-based EffectivCRT(TM) during AF algorithm improves therapy delivery in heart failure patients with atrial fibrillation (AF). The results were presented at the 2016 European Society of Cardiology (ESC) Congress in Rome.

Amsterdam, Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA) today announced its sponsorship of the documentary COPD: Highly Illogical - Remembering Leonard Nimoy. The documentary seeks to educate viewers about COPD through Leonard Nimoy’s personal story of courage, while also providing the latest information about treatments for the chronic disease.

PR Newswire, CINCINNATI, Aug. 22, 2016: Ethicon*, a trusted leader in advancing wound closure, announces the launch of STRATAFIX™ Spiral PDS Plus and STRATAFIX™ Spiral Monocryl Plus Knotless Tissue Control Devices. 

DUBLIN - Aug. 26, 2016 - Medtronic plc (NYSE: MDT), on behalf of its indirect, wholly-owned subsidiary HeartWare International, Inc., today announced that, in connection with the completion of the acquisition of HeartWare by Medtronic, HeartWare has commenced an offer to repurchase (the "Convertible Notes Repurchase Offer"), at the option of each holder, any and all of its outstanding 3.50% Convertible Senior Notes due 2017 (the "2017 Notes") and 1.75% Convertible Senior Notes due 2021 (the "2021 Notes," and together with the 2017 Notes, the "Notes"). 

DUBLIN - Aug. 23, 2016 - Medtronic plc (NYSE: MDT), the global leader in medical technology, has completed its acquisition of HeartWare International, Inc., a leading innovator of less-invasive, miniaturized, mechanical circulatory support technologies (MCS) for treating patients with advanced heart failure.

Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today the first two patients with abdominal aortic aneurysms (“AAA”) have been treated with the Ovation Alto™ Abdominal Stent Graft System. The patients were treated by Andrew Holden, MD, and Andrew Hill, MD, of Auckland City Hospital, Auckland, New Zealand.

Minneapolis, MN, Aug. 11, 2016 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (OTCQB: BSGM), a medical device company developing the PURE EP(TM) System, a novel cardiac electrophysiology (EP) information system, today announced the Journal of the American College of Cardiology: Clinical Electrophysiology has published an article entitled “Novel Electrophysiology Signal Recording System Enables Specific Visualization of the Purkinje Network and Other High-Frequency Signals” by Ammar M. Killu, MBBS, Niyada Naksuk, MD, Kalpathi L. Venkatachalam, MD, and Samuel J. Asirvatham, MD from Mayo Clinic.

IRVINE, Calif., July 27, 2016 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced that Health Canada has approved the Edwards SAPIEN 3 transcatheter heart valve for the treatment of patients living with severe, symptomatic aortic stenosis and at high or greater risk for surgical aortic valve replacement.

REDWOOD CITY, Calif. – July 21, 2016 – Providence Health Care has become the first center in Canada to adopt the HeartFlow® FFRct Analysis, and also first in the world to utilize the next generation version of the platform. The HeartFlow FFRct Analysis, which was recently approved by Health Canada, is a novel, non-invasive technology used by clinicians to assess their patients for coronary artery disease. 

WALTHAM, MA – July 5, 2016 – Corindus Vascular Robotics, Inc. [NYSE MKT: CVRS], a leading developer of precision vascular robotics, announced that its CorPath® System will be highlighted in several presentations on new therapies and techniques for the treatment of high-risk patients with complex cardiovascular disease at SDCI 2016: San Diego Cardiovascular Interventions Course, July 8 and 9, at the Estancia La Jolla Hotel & Spa, La Jolla, CA. Corindus' CorPath System, the first FDA-cleared medical device to bring robotically-assisted precision to radial, coronary and peripheral procedures, will be featured in two live robotic-assisted complex percutaneous coronary interventions (PCIs) during the course.

DUBLIN - July 13, 2016 - Medtronic plc (NYSE: MDT) has received U.S. Food and Drug Administration (FDA) approval for the IN.PACT(TM) Admiral(TM) drug-coated balloon (DCB) in longer, 150 mm lengths. The new 150 mm length balloon, available in four, five, and six mm diameters, will provide greater treatment options for long lesions in patients with peripheral artery disease (PAD). 

July 13, 2016 — Stereotaxis, Inc., a global leader in innovative technologies for the treatment of cardiac arrhythmias, today announced that the University of Chicago Medicine will implement the Company’s Niobe ES remote magnetic navigation system as part of its vision to create a cutting-edge arrhythmia technology suite. 

LOS ANGELES, July 12, 2016 /PRNewswire-USNewswire/ --  Good Samaritan Hospital is the first hospital on the West Coast to offer patients with coronary artery disease (CAD) a first-of-its-kind dissolving heart stent.   Abbott's Absorb™ dissolving heart stent is a drug eluting coronary stent that dissolves, completely and naturally, in the body over time.  Absorb™ treats coronary artery disease like a metallic stent, propping the diseased vessel open to restore1 blood flow, but then disappears after the artery is healed, leaving no metal behind to restrict natural vessel motion.

TAMPA, Fla., July 13, 2016 /PRNewswire/ -- CareDx, Inc. (NASDAQ: CDNA), a molecular diagnostics company, today called for Medicare Administrative Contractor First Coast Service Options, Inc. to reverse its recent proposal to drastically reduce reimbursement for its FDA-cleared diagnostic test AlloMap, which measures gene expression levels to help clinicians determine a heart transplant recipient's risk for organ rejection. 

WINSTON-SALEM, N.C., June 23, 2016 /PRNewswire-USNewswire/ -- Researchers at Wake Forest Baptist Medical Center have developed a medical app for risk-evaluation and clinical support that can help emergency department personnel more efficiently determine which patients with acute chest pain can be discharged safely. 

DUBLIN - June 28, 2016 - Medtronic plc (NYSE:MDT) today announced availability of its Beacon Heart Failure Management Service in the United States. This new service from Medtronic Care Management Services (MCMS) combines data from Medtronic implantable cardioverter defibrillator (ICD) or cardiac resynchronization therapy (CRT) devices with post-acute monitoring from MCMS, enabling providers to focus on heart failure patients with the greatest risk and evaluate early intervention before a heart failure event occurs. 

SAN RAMON, Calif., June 17, 2016 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug product candidates to treat orphan and high-value diseases with unmet parenteral delivery needs, today announced that it has launched the PHenomenal campaign, which gives people with PH and their loved ones the opportunity to submit photos and videos of themselves showing what makes them interesting and inspiring. To learn more about PH and the PHenomenal campaign, please visit http://youtube.com/c/SteadymedPHenomSelf. 

LAS VEGAS, June 20, 2016 /PRNewswire/ -- Nevada Heart and Vascular Center is proud to congratulate Chowdhury H. Ahsan, M.D., F.A.C.C. F.S.C.A.I. for his recent election to Alpha Omega Alpha, the medical honor society. This honor was awarded by medical students, residents and faculty members from University of Nevada School of Medicine to recognize Dr. Ahsan's academic excellence, dedication to medicine as a profession, and service to patients. Dr. Ahsan received this prestigious award as result of his work as director of the Cardiology Fellowship program at the university.

COLUMBIA, Mo. (June 15, 2016) ― As men and women grow older, their chances for coronary heart disease also increase. Atherosclerosis is a condition in which plaque builds up inside the arteries, which can lead to serious problems, including heart attacks, strokes or even death. Now, researchers at the University of Missouri have found that Insulin-like Growth Factor-1 (IGF-1), a protein that is naturally found in high levels among adolescents, can help prevent arteries from clogging. They say that increasing atherosclerosis patients’ levels of the protein could reduce the amount of plaque buildup in their arteries, lowering their risk of heart disease.

SAN RAMON, Calif., June 16, 2016 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug product candidates to treat orphan and high-value diseases with unmet parenteral delivery needs, today announced that it has launched the PHenomenal campaign, which gives people with PH and their loved ones the opportunity to submit photos and videos of themselves showing what makes them interesting and inspiring. To learn more about PH and the PHenomenal campaign, please visit www.youtube.com/user/phenomself.

DUBLIN and NEW ORLEANS - June 10, 2016 - Delivering on its vision to transform care for the millions currently living with diabetes through intelligent data, Medtronic plc (NYSE:MDT) announced new product developments and technology partnerships at the American Diabetes Association (ADA) 76th Scientific Sessions that will create meaningful insights for providers and people with diabetes.